As the world celebrates the one-year anniversary of the very first dose of the Pfizer vaccine to be given outside of clinical trials, we reflect on the enormous progress that has been made twelve months on.
New findings from the Oxford-led Com-COV2 trial have found that a first course of vaccine consisting of AstraZeneca then Novavax offers very strong protection against COVID-19.
New research has shown how the body’s precise immune response to SARS-CoV-2 is shaped by the pattern of exposure to different variants and vaccinations.
A team of scientists from Cardiff and the US have identified the biological mechanism that causes extremely rare blood clots following a dose of the AstraZeneca vaccine.
The National Institute for Health Research has today announced a new study to understand what causes rare cases of blood clotting following vaccination for COVID-19.
The Oxford scientists who worked on the design and development of the Oxford/AstraZeneca COVID-19 vaccine have been awarded a special accolade by the British Society for Immunology.